Celltrion presents infliximab data at ECCO Congress

Celltrion Healthcare presented new data at the 18th European Crohn’s and Colitis Organisation (ECCO) annual congress in Copenhagen, Denmark. The data demonstrate the safety and efficacy of subcutaneous (SC) infliximab (CT-P13 SC) in patients with inflammatory bowel disease (IBD).